Search Results
Jul 02, 2026, 15:37 ET Are NUVL, ROKU, PAYO, HUN Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-nuvl-roku-payo-hun-obtaining-fair-deals-for-their-shareholders-302817103.htmlSOURCE
More news about: Halper Sadeh LLP
Jun 25, 2026, 13:56 ET Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-nuvl-cprx-tmhc-obtaining-fair-deals-for-their-shareholders-302810930.htmlSOURCE
More news about: Halper Sadeh LLP
Jun 24, 2026, 15:36 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TMHC, NUVL, AXTA, and PFLC
NUVL) related to its sale to GSK plc. Under the terms of the proposed transaction, Nuvalent shareholders are expected to receive $124.00 per share
More news about: Monteverde & Associates PC
Jun 22, 2026, 17:07 ET Are ROKU, SLP, NUVL, DAN Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-roku-slp-nuvl-dan-obtaining-fair-deals-for-their-shareholders-302806745.htmlSOURCE
More news about: Halper Sadeh LLP
Jun 18, 2026, 11:28 ET Are NUVL, DAN, PAYO Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-nuvl-dan-payo-obtaining-fair-deals-for-their-shareholders-302804429.htmlSOURCE
More news about: Halper Sadeh LLP
Jun 17, 2026, 13:50 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--SUNE, NUVL, CCRN, and BGMS
NUVL) related to its sale to GSK plc. Under the terms of the proposed transaction, Nuvalent shareholders are expected to receive $124.00 per share
More news about: Monteverde & Associates PC
Jun 12, 2026, 11:47 ET Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-avns-nuvl-xoma-tbrg-obtaining-fair-deals-for-their-shareholders-302799081.htmlSOURCE
More news about: Halper Sadeh LLP
Jun 10, 2026, 10:45 ET Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders
MILWAUKEE, June 10, 2026 /PRNewswire/ -- Ademi LLP is investigating Nuvalent (NASDAQ: NUVL) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with GSK plc.
More news about: Ademi LLP
May 27, 2026, 06:30 ET Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC
May 27, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,
More news about: Nuvalent, Inc.
May 21, 2026, 17:23 ET Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting
May 21, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,
More news about: Nuvalent, Inc.
May 07, 2026, 06:30 ET Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results
May 7, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,
More news about: Nuvalent, Inc.
Apr 21, 2026, 10:32 ET Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting
April 21, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,
More news about: Nuvalent, Inc.
Apr 17, 2026, 16:01 ET New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
April 17, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,
More news about: Nuvalent, Inc.
Apr 07, 2026, 06:30 ET Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
April 7, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,
More news about: Nuvalent, Inc.
Mar 17, 2026, 17:15 ET Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026
March 17, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,
More news about: Nuvalent, Inc.
Feb 26, 2026, 06:30 ET Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results
Feb. 26, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,
More news about: Nuvalent, Inc.
Feb 05, 2026, 06:30 ET Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Feb. 5, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,
More news about: Nuvalent, Inc.
Jan 12, 2026, 06:30 ET Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones
Jan. 12, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,
More news about: Nuvalent, Inc.
Dec 22, 2025, 06:30 ET Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference
Dec. 22, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,
More news about: Nuvalent, Inc.
Dec 10, 2025, 16:01 ET Nuvalent Appoints Ron Squarer to Board of Directors
Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,
More news about: Nuvalent, Inc.
Nov 26, 2025, 06:30 ET Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference
Nov. 26, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,
More news about: Nuvalent, Inc.
Nov 24, 2025, 16:01 ET Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders
CAMBRIDGE, Mass., Nov. 24, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,
More news about: Nuvalent, Inc.
Nov 19, 2025, 16:19 ET Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
Nov. 19, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,
More news about: Nuvalent, Inc.
Nov 18, 2025, 23:50 ET Nuvalent Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., Nov. 18, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,
More news about: Nuvalent, Inc.
Nov 17, 2025, 16:01 ET Nuvalent Announces Public Offering of Common Stock
CAMBRIDGE, Mass., Nov. 17, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced
More news about: Nuvalent, Inc.